Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SKP-0141 in Severe Hemophilia A
NCT06738901Phase 3Not yet recruiting
- Sponsor
- SK Plasma
- Start
- Mar 2025
- Primary completion
- Jul 2026
- Modality
- Blood Coagulation Factors
01
Overview
Phase 3, open-label, single-arm trial of SKP-0141 in hemophilia A, sponsored by SK Plasma. Primary endpoint: Annualized Bleeding Rate up to 25 weeks. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
SKP-0141
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT06738901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06738901.